EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinician’s Guide to Using Ozanimod for the Treatment of Ulcerative Colitis

Bruce E Sands, Stefan Schreiber, Irina Blumenstein, Michael V Chiorean, Ryan C Ungaro iD, David T Rubin iD

Journal of Crohn's and Colitis · 30.12.2023 · 17 (12) · 2012-2025

DOI: 10.1093/ecco-jcc/jjad112 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Crohn's and Colitis, online erschienen am 12.07.2023. Verfasst von Bruce E Sands und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb, Princeton.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of advanced therapies [eg, biologics, Janus kinase inhibitors] over the past few decades has revolutionised the treatment of ulcerative colitis. However, the limitations of these therapies leave an unmet need for safer and more effective or convenient treatment options. There is growing interest in the development of novel oral small molecule therapies for the treatment of ulcerative colitis. Ozanimod is an oral small molecule therapy that is approved in the USA, the European Union, and other countries as the first sphingosine 1-phosphate receptor modulator for the treatment of moderately to severely active ulcerative colitis in adults. This review provides guidance for ozanimod use for the treatment of ulcerative colitis, based on the prescribing information, clinical trial and real-world data, and the authors’ clinical experiences. This guidance outlines patient characteristics to consider when deciding if ozanimod treatment is suitable and describes how to educate patients on risks and best practices. It also details the nature and frequency of monitoring during treatment, which should be adapted to the individual patient based on pre-existing risk factors and events that possibly occur during treatment. This review also provides insights into the patient characteristics and clinical scenarios best suited for ozanimod treatment, based on its efficacy, safety profile, and risks compared with other therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeAdultHumansIndansOxadiazolesImmunologic Factors

Stichwörter der Autor:innen

S1P receptor modulatorUlcerative colitisozanimod

Substanzen

ozanimodIndansOxadiazolesImmunologic Factors

Autor:innen und Institutionen

  • Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany.
  • Medical Clinic 1, Department of Gastroenterology, Hepatology and Clinical Nutrition, Goethe University Hospital, Frankfurt, Germany.
  • Department of Gastroenterology, Swedish Medical Center, Seattle, WA, USA.
  • Section of Gastroenterology, Hepatology & Nutrition, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.

ORCID-Profile: Ryan C Ungaro, David T Rubin

Förderung

  • Bristol Myers Squibb, Princeton

Zitieren

APA

Sands, B. E., Schreiber, S., Blumenstein, I., Chiorean, M. V., Ungaro, R. C., & Rubin, D. T. (2023). Clinician’s Guide to Using Ozanimod for the Treatment of Ulcerative Colitis. Journal of Crohn's and Colitis, 17(12), 2012-2025. https://doi.org/10.1093/ecco-jcc/jjad112

Vancouver

Sands BE, Schreiber S, Blumenstein I, Chiorean MV, Ungaro RC, Rubin DT. Clinician’s Guide to Using Ozanimod for the Treatment of Ulcerative Colitis. Journal of Crohn's and Colitis. 2023;17(12):2012-2025. doi:10.1093/ecco-jcc/jjad112

BibTeX
@article{Sands2023,
  author = {Sands, Bruce E and Schreiber, Stefan and Blumenstein, Irina and Chiorean, Michael V and Ungaro, Ryan C and Rubin, David T},
  title = {Clinician’s Guide to Using Ozanimod for the Treatment of Ulcerative Colitis},
  journal = {Journal of Crohn's and Colitis},
  year = {2023},
  volume = {17},
  number = {12},
  pages = {2012--2025},
  doi = {10.1093/ecco-jcc/jjad112}
}
Kostenlos starten →